CARLSBAD, Calif., Jan. 2, 2019 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense
therapeutics, today announced that Management will present a
Company overview at the 37th Annual J.P. Morgan
Healthcare Conference on Monday, January 7,
2019 at 4:00 p.m. PT in
San Francisco, CA.
A live audio webcast of the presentation will be available on
the Investors & Media section of the Company's website,
www.ionispharma.com. A replay will be available on the Ionis
website within 24 hours and will be archived for a limited
time.
ABOUT IONIS PHARMACEUTICALS, INC.
As the leader in
RNA-targeted drug discovery and development, Ionis has created an
efficient, broadly applicable, proprietary antisense technology
platform with the potential to treat diseases where no other
therapeutic approaches have proven effective. Our drug discovery
platform has served as a springboard for actionable promise and
realized hope for patients with unmet needs – such as children and
adults with spinal muscular atrophy (SMA). We created
SPINRAZA® (nusinersen)* and are proud to have
brought new hope to the SMA community by developing the first and
only approved treatment for this disease.
Our sights are set on all the patients we have yet to reach with
a pipeline of more than 40 drugs with the potential to treat
patients with cardiovascular disease, rare diseases, neurological
diseases, infectious diseases and cancer. We created TEGSEDI™
(inotersen) the world's first RNA-targeted therapeutic approved for
the treatment of polyneuropathy of hereditary transthyretin (TTR)
amyloidosis (ATTR) in adult patients that our affiliate Akcea
Therapeutics is commercializing. Together with Akcea, we are
also bringing new medicines to patients with cardiometabolic lipid
disorders.
To learn more about Ionis follow us on twitter @ionispharma or
visit http://ir.ionispharma.com/.
*Spinraza is marketed by Biogen.
IONIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding Ionis
Pharmaceuticals' business and the therapeutic and commercial
potential of Ionis' technologies, products in development and
commercial products, including SPINRAZA® and
TEGSEDI™ (inotersen). Any statement describing Ionis' goals,
expectations, financial or other projections, intentions or beliefs
is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. Ionis' forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking statements.
Although Ionis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
facts and factors currently known by Ionis. As a result, you are
cautioned not to rely on these forward-looking statements. These
and other risks concerning Ionis' programs are described in
additional detail in Ionis' annual report on Form 10-K for the year
ended December 31, 2017, and most recent Form 10-Q quarterly
filing, which are on file with the SEC. Copies of this and
other documents are available from the Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis
Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark
of Akcea Therapeutics, Inc. TEGSEDI™ is a trademark
of Akcea Therapeutics, Inc. SPINRAZA® is
a registered trademark of Biogen.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-present-at-37th-annual-jp-morgan-healthcare-conference-300771321.html
SOURCE Ionis Pharmaceuticals, Inc.